The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we ...

A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors. BRAF ...

Combination CDK4/6 and MEK inhibitor treatment reduced tumor growth in mouse models of melanoma with acquired resistance to BRAF and MEK inhibition. A preclinical study published in Molecular Cancer ...

A multicenter study of central nervous system (CNS) metastasis in EGFR-mutated advanced non–small-cell lung cancer in Thailand: CNS progression-free survival analysis. This is an ASCO Meeting Abstract ...

A BRAF-MEK inhibitors are a chemical or drug that restricts the mitogen-activated protein kinase and kinase, enzymes MEK1 and/or MEK2. The chemicals are used to affect the BRAF-MEK pathway which is ...

BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...

A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain ...

Single-agent BRAF-inhibitor therapy has a proven survival benefit for patients with advanced-stage melanoma and is approved for this indication; however, downsides of this approach are early acquired ...

Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar ® (dabrafenib) + Mekinist ® (trametinib) for the treatment of adult ...

Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with ...

MADRID — For patients with advanced melanoma that is BRAF-mutation positive, the combination of a BRAF and MEK inhibitor works better than a BRAF inhibitor alone. The data come from 2 phase 3 trials ...

Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.